CoChat

IGF1 receptor inhibition amplifies the effects of cancer drugs by autophagy and immune-dependent mechanisms

Open access

The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Pharmacological autophagy enhancement constitutes a preclinically validated strategy for preventing or treating most major age-associated diseases. Driven by this consideration, we performed a high-content/high-throughput screen on 65 000 distinct compounds on a robotized fluorescence microscopy platform to identify novel autophagy inducers. RESULTS: Here, we report the discovery of picropodophyllin (PPP) as a potent inducer of autophagic flux that acts on-target, as an inhibitor of the tyrosine kinase activity of the insulin-like growth factor-1 receptor (IGF1R). Thus, PPP lost its autophagy-stimulatory activity in cells engineered to lack IGF1R or to express a constitutively active AKT serine/threonine kinase 1 (AKT1) mutant. When administered to cancer-bearing mice, PPP improved the therapeutic efficacy of chemoimmunotherapy with a combination of immunogenic cytotoxicants and programmed cell death 1 (PDCD1, better known as PD-1) blockade. These PPP effects were lost when tumors were rendered PPP-insensitive or autophagy-incompetent. In combination with chemotherapy, PPP enhanced the infiltration of tumors by cytotoxic T lymphocytes, while reducing regulatory T cells. In human triple-negative breast cancer patients, the activating phosphorylation of IGF1R correlated with inhibited autophagy, an unfavorable local immune profile, and poor prognosis. CONCLUSION: Altogether, these results suggest that IGF1R may constitute a novel and druggable therapeutic target for the treatment of cancer in conjunction with chemoimmunotherapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/jitc-2021-002722

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Identification of picropodophyllin (PPP) as autophagy inducer. (A) Human osteosarcoma U2OS stably expressing GFP-LC3 cells and were treated with a chemical library of 65 000 diverse compounds (10 μM) for 6 hours. Torin 1 at 300 nM was used as positive control for autophagy induction. The number of GFP-LC3 positive puncta was measured as a proxy for autophagy and the number of cells that confer a regular nuclear phenotype was assessed as an indicator for viability. We selected the agents that dramatically increase the expression of GFP-LC3 and whose viability is >0.5 times of its expression in control group, are potential autophagy activators. Data were normalized to controls, depicted as means of each campaign. (B, C) U2OS cells stably expressing GFP-LC3 were treated with PPP (1, 2.5, 5, 10 μM) and torin1 (300 nm) was used as control. the surface of GFP-LC3 positive puncta was measured as a proxy for autophagy (C) and representative images are depicted in B. scale bar equals 10 µm. (D, E) Rat adrenal gland PC12 cells expressing an inducible variant of Q74-GFP were treated with doxycycline (1 μg/mL) for 8 hours for the induction of Q74 expression. Then the medium was changed and PPP was added at 1, 2.5, 5 and 10 μM. Torin1 (300 nm) was used as positive control. data is depicted as barchart in E and representative images are shown in D. Scale bar equals 10 µm. (F, G) U2OS cells were treated with PPP and the positive control torin1 (300 nm) for 6 hours, followed by the incubation with specific antibodies to block acetylated tubulin. Thereafter, immunofluorescence was conducted with antibodies against acetylated lysine residues and appropriate AlexaFluor-conjugated secondary antibodies. representative images of acetylation are shown in F, and acetylation intensity in the cytoplasm was measured in G. Scale bar equals 10 µm. Data are means±SD of three replicates (**p<0.01, ***p<0.001 vs DMSO/Ctr, Student’s t-test).
Figure 1 Identification of picropodophyllin (PPP) as autophagy inducer. (A) Human osteosarcoma U2OS stably expressing GFP-LC3 cells and were treated with a chemical library of 65 000 diverse compounds (10 μM) for 6 hours. Torin 1 at 300 nM was used as positive control for autophagy induction. The number of GFP-LC3 positive puncta was measured as a proxy for autophagy and the number of cells that confer a regular nuclear phenotype was assessed as an indicator for viability. We selected the agents that dramatically increase the expression of GFP-LC3 and whose viability is >0.5 times of its expression in control group, are potential autophagy activators. Data were normalized to controls, depicted as means of each campaign. (B, C) U2OS cells stably expressing GFP-LC3 were treated with PPP (1, 2.5, 5, 10 μM) and torin1 (300 nm) was used as control. the surface of GFP-LC3 positive puncta was measured as a proxy for autophagy (C) and representative images are depicted in B. scale bar equals 10 µm. (D, E) Rat adrenal gland PC12 cells expressing an inducible variant of Q74-GFP were treated with doxycycline (1 μg/mL) for 8 hours for the induction of Q74 expression. Then the medium was changed and PPP was added at 1, 2.5, 5 and 10 μM. Torin1 (300 nm) was used as positive control. data is depicted as barchart in E and representative images are shown in D. Scale bar equals 10 µm. (F, G) U2OS cells were treated with PPP and the positive control torin1 (300 nm) for 6 hours, followed by the incubation with specific antibodies to block acetylated tubulin. Thereafter, immunofluorescence was conducted with antibodies against acetylated lysine residues and appropriate AlexaFluor-conjugated secondary antibodies. representative images of acetylation are shown in F, and acetylation intensity in the cytoplasm was measured in G. Scale bar equals 10 µm. Data are means±SD of three replicates (**p<0.01, ***p<0.001 vs DMSO/Ctr, Student’s t-test).CC BY-NC · PubMed Central
Figure 2 TFEB and TFE3 mediate PPP-induced autophagy. (A–C) U2OS-GFP-LC3 wild-type (WT) or ATG5 knockout cells were treated with PPP (10 μM) or torin1 (300 nM) for 6 hours. Then the cells were fixed and GFP-LC3 dots were quantified. Scale bar equals 10 μm. Data are means ± SD of four replicates ***p<0.001 vs untreated control; ###P<0.001 vs WT; Tukey’s multiple comparisons test). (D, E) U2OS cells stably expressing GFP-TFEB fusion protein were treated with PPP (10 μM) for 16 hours and torin1 was used as positive control. nuclear GFP intensities were measured (E) and representative images are shown in D. Scale bar equals 10 µm. Data are means±SD of three replicates (**p<0.01, ***p<0.001 vs DMSO/Ctr, Student’s t-test). (F, G) U2OS cells were treated with PPP (10 μM) for 16 hours and torin1 was used as positive control and then endogenous TFE3 translocation was assessed by immunostaining (F) and TFE3 nuclear intensities are depicted (G). Scale bar equals 10 µm. Data are means±SD of three replicates (**p<0.01, ***p<0.001 vs DMSO/Ctr, Student’s t-test). (H) U2OS cells were treated with PPP (10 μM) for 16 hours or were left untreated. Cytoplasmic and nuclear fractions were separated and assessed for nuclear translocation of TFEB and TFE3 by SDS-PAGE. band intensities of TFEB, TFE3, GAPDH and H3 were assessed and their ratio (TFEB or TFE3/GAPDH, and TFEB or TFE3/H3) was calculated (online supplemental figure S3). (I–Q) U2OS-GFP-LC3 cells WT or single as well as double knockout for TFEB and TFE3 were treated with PPP (10 μM) or torin1 for 16 H. LC3 II expression and TFEB/TFE3 deficiency by knockout were checked by SDS-PAGE and parallel immunoblot (K, N, Q). Band intensities of LC3-II and β-actin (ACTB) were assessed, and their ratio (LC3-II/actin) was calculated (online supplemental figure S3). representative images are shown in (I, L, O), and GFP-LC3 dots were quantified as indicator of autophagy (J, M, P). Scale bar equals 10 μm. Data are means±SD of four replicates (***p<0.001 vs untreated control; #P<0.05, ##P<0.01, ###P<0.001 vs WT; Tukey’s multiple comparisons test). PPP, picropodophyllin SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis.
Figure 2 TFEB and TFE3 mediate PPP-induced autophagy. (A–C) U2OS-GFP-LC3 wild-type (WT) or ATG5 knockout cells were treated with PPP (10 μM) or torin1 (300 nM) for 6 hours. Then the cells were fixed and GFP-LC3 dots were quantified. Scale bar equals 10 μm. Data are means ± SD of four replicates ***p<0.001 vs untreated control; ###P<0.001 vs WT; Tukey’s multiple comparisons test). (D, E) U2OS cells stably expressing GFP-TFEB fusion protein were treated with PPP (10 μM) for 16 hours and torin1 was used as positive control. nuclear GFP intensities were measured (E) and representative images are shown in D. Scale bar equals 10 µm. Data are means±SD of three replicates (**p<0.01, ***p<0.001 vs DMSO/Ctr, Student’s t-test). (F, G) U2OS cells were treated with PPP (10 μM) for 16 hours and torin1 was used as positive control and then endogenous TFE3 translocation was assessed by immunostaining (F) and TFE3 nuclear intensities are depicted (G). Scale bar equals 10 µm. Data are means±SD of three replicates (**p<0.01, ***p<0.001 vs DMSO/Ctr, Student’s t-test). (H) U2OS cells were treated with PPP (10 μM) for 16 hours or were left untreated. Cytoplasmic and nuclear fractions were separated and assessed for nuclear translocation of TFEB and TFE3 by SDS-PAGE. band intensities of TFEB, TFE3, GAPDH and H3 were assessed and their ratio (TFEB or TFE3/GAPDH, and TFEB or TFE3/H3) was calculated (online supplemental figure S3). (I–Q) U2OS-GFP-LC3 cells WT or single as well as double knockout for TFEB and TFE3 were treated with PPP (10 μM) or torin1 for 16 H. LC3 II expression and TFEB/TFE3 deficiency by knockout were checked by SDS-PAGE and parallel immunoblot (K, N, Q). Band intensities of LC3-II and β-actin (ACTB) were assessed, and their ratio (LC3-II/actin) was calculated (online supplemental figure S3). representative images are shown in (I, L, O), and GFP-LC3 dots were quantified as indicator of autophagy (J, M, P). Scale bar equals 10 μm. Data are means±SD of four replicates (***p<0.001 vs untreated control; #P<0.05, ##P<0.01, ###P<0.001 vs WT; Tukey’s multiple comparisons test). PPP, picropodophyllin SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis.CC BY-NC · PubMed Central
Figure 3 PPP induces autophagy via IGF1R/AKT signaling. (A, B) U2OS-GFP-LC3 cells were incubated in the absence of FBS overnight and were further treated with PPP (10 μM) or torin1 (300 nm) in the presence or absence of IGF1 (10 nm) for 6 hours. After fixation, GFP-LC3 dots were quantified in B. Scale bar equals 10 μm. Data are means±SD of three replicates (**P<0.01, vs DMSO/Ctr, Student’s t-test). (C) Immunoblot exploration of the IGF1R signal pathway. After U2OS cells were incubated in the absence of FBS overnight, then the cells were treated with PPP (10 μM) together with or without IGF1 (10 nm) for 6 hours. Proteins were separated by SDS-PAGE and parallel immunoblots of pIGF1R (Tyr1135/1136), IGF1R, pAkt (Ser473), Akt, pmTOR (Ser2448), mTOR, pp70 (THR389), p70, pTFEB (Ser211), TFEB, LC3-II and were performed in parallel instances and β-actin (ACTB) was used as loading control (C). (D, E) U2OS wild-type (WT) or IGF1R knockout cells were treated with PPP (10 μM) for 6 H. SDS-PAGE and immunoblots of IGF1R, LC3 and ACTB were performed (D), band intensities of LC3-II and ACTB were assessed, and their ratio (LC3-II/ACTB) was calculated (online supplemental figure S4). In parallel U2OS-GFP-LC3 WT or IGF1R knockout cells were treated with PPP (10 μM) for 6 hours then the cells were fixed and GFP-LC3 dots were quantified by microscopy (F). Representative images are shown in E and scale bar equals 10 μm. Data are means±SD of three replicates (***P<0.001 vs untreated control; ##P<0.01 vs WT; Tukey’s multiple comparisons test). (G–I) U2OS cells were transfected with constitutive active AKTT308D/S473D and were treated with PPP (10 μM) for 6 hours. SDS-PAGE and immunoblots of pAKT, AKT, LC3 and ACTB were performed (G), band intensities of LC3-II and ACTB were assessed, and their ratio (LC3-II/ACTB) was calculated (online supplemental figure S4). In parallel U2OS-GFP-LC3 WT or AKTT308D/S473D-expressing cells were treated with PPP (10 μM) for 6 H then the cells were fixed and GFP-LC3 dots were quantified by microscopy (I). Representative images are shown in H and scale bar equals 10 μm. Data are means±SD of three replicates (**P<0.01 vs untreated control; ##P<0.01 vs WT; Tukey’s multiple comparisons test). (J–K) U2OS cells stably expressing GFP-AKT or GFP-AKTR25C were incubated in absence of FBS overnight, then the cells were treated with IGF1 (10 nm) or PPP (10 μM) combined with IGF1 (10 nm). After 5 min, the membrane translocation of GFP-AKT was detected by microscopy (J) and the membrane intensity of AKT was measured (K). Scale bar equals 10 μm. Data are means±SD of three replicates (***P<0.001 vs DMSO/Ctr, Student’s t-test). IGF1, FBS, fetal bovine serum; IGF1, insulin-like growth factor-1; PPP, picropodophyllin; SDS_PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis.
Figure 3 PPP induces autophagy via IGF1R/AKT signaling. (A, B) U2OS-GFP-LC3 cells were incubated in the absence of FBS overnight and were further treated with PPP (10 μM) or torin1 (300 nm) in the presence or absence of IGF1 (10 nm) for 6 hours. After fixation, GFP-LC3 dots were quantified in B. Scale bar equals 10 μm. Data are means±SD of three replicates (**P<0.01, vs DMSO/Ctr, Student’s t-test). (C) Immunoblot exploration of the IGF1R signal pathway. After U2OS cells were incubated in the absence of FBS overnight, then the cells were treated with PPP (10 μM) together with or without IGF1 (10 nm) for 6 hours. Proteins were separated by SDS-PAGE and parallel immunoblots of pIGF1R (Tyr1135/1136), IGF1R, pAkt (Ser473), Akt, pmTOR (Ser2448), mTOR, pp70 (THR389), p70, pTFEB (Ser211), TFEB, LC3-II and were performed in parallel instances and β-actin (ACTB) was used as loading control (C). (D, E) U2OS wild-type (WT) or IGF1R knockout cells were treated with PPP (10 μM) for 6 H. SDS-PAGE and immunoblots of IGF1R, LC3 and ACTB were performed (D), band intensities of LC3-II and ACTB were assessed, and their ratio (LC3-II/ACTB) was calculated (online supplemental figure S4). In parallel U2OS-GFP-LC3 WT or IGF1R knockout cells were treated with PPP (10 μM) for 6 hours then the cells were fixed and GFP-LC3 dots were quantified by microscopy (F). Representative images are shown in E and scale bar equals 10 μm. Data are means±SD of three replicates (***P<0.001 vs untreated control; ##P<0.01 vs WT; Tukey’s multiple comparisons test). (G–I) U2OS cells were transfected with constitutive active AKTT308D/S473D and were treated with PPP (10 μM) for 6 hours. SDS-PAGE and immunoblots of pAKT, AKT, LC3 and ACTB were performed (G), band intensities of LC3-II and ACTB were assessed, and their ratio (LC3-II/ACTB) was calculated (online supplemental figure S4). In parallel U2OS-GFP-LC3 WT or AKTT308D/S473D-expressing cells were treated with PPP (10 μM) for 6 H then the cells were fixed and GFP-LC3 dots were quantified by microscopy (I). Representative images are shown in H and scale bar equals 10 μm. Data are means±SD of three replicates (**P<0.01 vs untreated control; ##P<0.01 vs WT; Tukey’s multiple comparisons test). (J–K) U2OS cells stably expressing GFP-AKT or GFP-AKTR25C were incubated in absence of FBS overnight, then the cells were treated with IGF1 (10 nm) or PPP (10 μM) combined with IGF1 (10 nm). After 5 min, the membrane translocation of GFP-AKT was detected by microscopy (J) and the membrane intensity of AKT was measured (K). Scale bar equals 10 μm. Data are means±SD of three replicates (***P<0.001 vs DMSO/Ctr, Student’s t-test). IGF1, FBS, fetal bovine serum; IGF1, insulin-like growth factor-1; PPP, picropodophyllin; SDS_PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis.CC BY-NC · PubMed Central
Figure 4 IGF1R signaling correlates with immunosuppressive markers and decreased survival in breast cancer. (A–I) The expression of CD163, FOXP3 and CD8 as well as the phosphorylation of IGF1R and the dot formation of LC3 were quantified in paraffin-embedded biopsies obtained from 49 triple-negative breast cancer patients by ImageJ after staining with specific antibodies. Representative images of phosphorylated-IGF1R, dotted LC3B, and CD163, FOXP3 and CD8 expression are shown in A. The scale bar indicates 100 μm. Correlation analyses (determined by the Spearman method) of the analyzed parameters for each patient are depicted in B–E. (F–I) Kaplan-Meier survival analysis of patients with biomarker-positive and biomarker-negative immunohistochemistry staining. IGF1R, insulin-like growth factor-1 receptor.
Figure 4 IGF1R signaling correlates with immunosuppressive markers and decreased survival in breast cancer. (A–I) The expression of CD163, FOXP3 and CD8 as well as the phosphorylation of IGF1R and the dot formation of LC3 were quantified in paraffin-embedded biopsies obtained from 49 triple-negative breast cancer patients by ImageJ after staining with specific antibodies. Representative images of phosphorylated-IGF1R, dotted LC3B, and CD163, FOXP3 and CD8 expression are shown in A. The scale bar indicates 100 μm. Correlation analyses (determined by the Spearman method) of the analyzed parameters for each patient are depicted in B–E. (F–I) Kaplan-Meier survival analysis of patients with biomarker-positive and biomarker-negative immunohistochemistry staining. IGF1R, insulin-like growth factor-1 receptor.CC BY-NC · PubMed Central
Figure 5 PPP improves autophagy-dependent anticancer chemotherapy in a T lymphocyte-dependent manner. (A, B) Human osteosarcoma cells were treated with PPP (10 μM) in the presence of a low dose of the ICD inducers mitoxantrone (MTX, 1 μM) for 6 hours. High-dose MTX (5 μM) was used as positive controls. Quinacrine staining was used to monitor intracellular ATP content. Representative images are shown in A and quinacrine dots were quantified in B. Scale bar equals 10 μm. Data are means±SD of three replicates (***p<0.001 vs untreated control; ###P<0.001 vs PPP; Tukey’s multiple comparisons test). (C–F) Human neuroglioma H4 cells wild-type or Atg5 knockout, human osteosarcoma U2OS wild type, PERK knockout or PEIF2α S51A knockin cells, murine fibrosarcoma MCA205 wild-type or AKTT308D/S473D knockin cells were treated with PPP (10 μM) alone or in combination with low doses of the ICD inducers MTX (1 μM) for 6 H as described above. High-dose MTX (5 μM) was used as positive controls. the extracellular ATP levels were measured in C–F. Data are means ± SD of three replicates (**P<0.01, ***P<0.001 vs untreated control; #P<0.05, ##P<0.01, ###P<0.001 vs WT; Tukey’s multiple comparisons test). (G–O) In vivo treatment of implanted murine MCA205 fibrosarcoma with oxaliplatin (OXA), anti-PD-1 antibody and PPP, alone or in combination (schematic view in G). (H, I) Growth kinetic of murine fibrosarcoma MCA205 cells evolving in immunocompetent C57BL/6 mice or athymic nu/nu mice (J) or MCA205 fibrosarcoma expressing constitutive active AKTT308D/S473D (M), Atg5 deficient MCA205 ATG5-/- (N) or MCA205 expressing the ectoATPase CD39 (O) evolving in immunocompetent C57BL/6 mice were treated as indicated in (G). When tumors became palpable, mice received systemic intraperitoneal (i.p.) injections of ppp alone or together with OXA or PD-1 blocker. Data are depicted as growth curves (mean±SD) (H, L–O) and tumor size distributions at day 24 (I). Individual tumor growth curves of mice treated with OXA and PPP, combined or not with PD-1 blockade are shown (K). The generation of immunological memory was assessed in cured animals by rechallenge with MCA205 and TC-1. Individual tumor growth curves are depicted (L). Data were analyzed with TumGrowth. n≥6 for mice in each group. (*P< 0.05 or ns, not statistically significant vs OXA; #P<0.05 or ns, not statistically significant vs OXA+PD-1 blockade, Student’s t-test, survival plots in online supplemental figure S7). (P) Schematic overview of the treatment of implanted murine MCA205 fibrosarcoma with OXA and PPP, alone or in combination. (P–T) Cytofluorometric analysis of tumor-infiltrating lymphocytes (TIL): CD3+CD8+ cytotoxic T lymphocytes (Q), CD8+PD-1+ T lymphocytes (R), CD4+FOXP3+CD25+ regulatory T cells (Treg) (S), and the ratio of CD3+CD8+ T cells over Treg (T). Data are means±SD (n≥5) (*p<0.05 or ns, not statistically significant vs control; #P<0.05 or ns, not statistically significant vs OXA, Student’s t-test). PPP, picropodophyllin.
Figure 5 PPP improves autophagy-dependent anticancer chemotherapy in a T lymphocyte-dependent manner. (A, B) Human osteosarcoma cells were treated with PPP (10 μM) in the presence of a low dose of the ICD inducers mitoxantrone (MTX, 1 μM) for 6 hours. High-dose MTX (5 μM) was used as positive controls. Quinacrine staining was used to monitor intracellular ATP content. Representative images are shown in A and quinacrine dots were quantified in B. Scale bar equals 10 μm. Data are means±SD of three replicates (***p<0.001 vs untreated control; ###P<0.001 vs PPP; Tukey’s multiple comparisons test). (C–F) Human neuroglioma H4 cells wild-type or Atg5 knockout, human osteosarcoma U2OS wild type, PERK knockout or PEIF2α S51A knockin cells, murine fibrosarcoma MCA205 wild-type or AKTT308D/S473D knockin cells were treated with PPP (10 μM) alone or in combination with low doses of the ICD inducers MTX (1 μM) for 6 H as described above. High-dose MTX (5 μM) was used as positive controls. the extracellular ATP levels were measured in C–F. Data are means ± SD of three replicates (**P<0.01, ***P<0.001 vs untreated control; #P<0.05, ##P<0.01, ###P<0.001 vs WT; Tukey’s multiple comparisons test). (G–O) In vivo treatment of implanted murine MCA205 fibrosarcoma with oxaliplatin (OXA), anti-PD-1 antibody and PPP, alone or in combination (schematic view in G). (H, I) Growth kinetic of murine fibrosarcoma MCA205 cells evolving in immunocompetent C57BL/6 mice or athymic nu/nu mice (J) or MCA205 fibrosarcoma expressing constitutive active AKTT308D/S473D (M), Atg5 deficient MCA205 ATG5-/- (N) or MCA205 expressing the ectoATPase CD39 (O) evolving in immunocompetent C57BL/6 mice were treated as indicated in (G). When tumors became palpable, mice received systemic intraperitoneal (i.p.) injections of ppp alone or together with OXA or PD-1 blocker. Data are depicted as growth curves (mean±SD) (H, L–O) and tumor size distributions at day 24 (I). Individual tumor growth curves of mice treated with OXA and PPP, combined or not with PD-1 blockade are shown (K). The generation of immunological memory was assessed in cured animals by rechallenge with MCA205 and TC-1. Individual tumor growth curves are depicted (L). Data were analyzed with TumGrowth. n≥6 for mice in each group. (*P< 0.05 or ns, not statistically significant vs OXA; #P<0.05 or ns, not statistically significant vs OXA+PD-1 blockade, Student’s t-test, survival plots in online supplemental figure S7). (P) Schematic overview of the treatment of implanted murine MCA205 fibrosarcoma with OXA and PPP, alone or in combination. (P–T) Cytofluorometric analysis of tumor-infiltrating lymphocytes (TIL): CD3+CD8+ cytotoxic T lymphocytes (Q), CD8+PD-1+ T lymphocytes (R), CD4+FOXP3+CD25+ regulatory T cells (Treg) (S), and the ratio of CD3+CD8+ T cells over Treg (T). Data are means±SD (n≥5) (*p<0.05 or ns, not statistically significant vs control; #P<0.05 or ns, not statistically significant vs OXA, Student’s t-test). PPP, picropodophyllin.CC BY-NC · PubMed Central
Figure 6 IGF1R inhibition improves the anticancer efficacy of immunotherapy. (A) Schematic overview of the in vivo treatment of murine lung cancer Tc1 cells with oxaliplatin (OXA), anti-PD-1 antibody and PPP, alone or in combination. (B–E) Growth kinetic of Tc1 cells evolving in immunocompetent C57BL/6 mice, treated as indicated in (A). When tumors became palpable, mice received systemic intraperitoneal injection of PPP alone or together with OXA or PD-1 blocker. Data ae depicted as (B) growth curves (mean±SD); (C) tumor size distributions at day 24; (D) individual tumor growth curves of mice treated with OXA and PPP, combined or not with PD-1 blockade. The generation of immunological memory was assessed in cured animals by rechallenge with MCA205 and Tc1. Individual tumor growth curves are depicted (E). Data were analyzed with TumGrowth. n≥ 6 for mice in each group. (*P<0.05 or ns, not statistically significant vs OXA; #P<0.05 or ns, not statistically significant vs OXA+PD-1 blocker, Student’s t-test, survival plots in online supplemental figure S7). (F) Schematic overview of the in vivo treatment of murine fibrosarcoma MCA205 cells with OXA, anti-PD-1 antibody and the selective of IGF1R inhibitor linsitinib (Lins), alone or in combination. IGF1R, insulin-like growth factor-1 receptor; PPP, picropodophyllin.
Figure 6 IGF1R inhibition improves the anticancer efficacy of immunotherapy. (A) Schematic overview of the in vivo treatment of murine lung cancer Tc1 cells with oxaliplatin (OXA), anti-PD-1 antibody and PPP, alone or in combination. (B–E) Growth kinetic of Tc1 cells evolving in immunocompetent C57BL/6 mice, treated as indicated in (A). When tumors became palpable, mice received systemic intraperitoneal injection of PPP alone or together with OXA or PD-1 blocker. Data ae depicted as (B) growth curves (mean±SD); (C) tumor size distributions at day 24; (D) individual tumor growth curves of mice treated with OXA and PPP, combined or not with PD-1 blockade. The generation of immunological memory was assessed in cured animals by rechallenge with MCA205 and Tc1. Individual tumor growth curves are depicted (E). Data were analyzed with TumGrowth. n≥ 6 for mice in each group. (*P<0.05 or ns, not statistically significant vs OXA; #P<0.05 or ns, not statistically significant vs OXA+PD-1 blocker, Student’s t-test, survival plots in online supplemental figure S7). (F) Schematic overview of the in vivo treatment of murine fibrosarcoma MCA205 cells with OXA, anti-PD-1 antibody and the selective of IGF1R inhibitor linsitinib (Lins), alone or in combination. IGF1R, insulin-like growth factor-1 receptor; PPP, picropodophyllin.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 64 references

Cited by

See all 83

Metadata

Authors
Wu, Q., Tian, A.-L., Li, B., Leduc, M., Forveille, S., Hamley, P., Galloway, W., Xie, W., Liu, P., Zhao, L., Zhang, S., Hui, P., Madeo, F., Tu, Y., Kepp, O., & Kroemer, G.
Affiliations
  • Inserm (FR)
  • Renmin Hospital of Wuhan University (CN)
  • Samsara Therapeutics Ltd, Oxford, UK
  • Centre de Recherche des Cordeliers, Equipe labellisée par la Ligue contre le cancer, Université de Paris, Sorbonne Université, Inserm U1138, Institut Universitaire de France, Paris, France
  • University of Graz (AT)
  • Karolinska University Hospital (SE)
Corresponding author
  • Tu, Yi
  • Kepp, Oliver
  • Kroemer, Guido
Venue
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Published
2021-06
Volume
9
Issue
6
Pages
e002722
ISSN
2051-1426 (ISSN-L)
OpenAlex
W3166418545
Cited by
83
References
64
Citations by year
2026: 9 · 2025: 16 · 2024: 17 · 2023: 16 · 2022: 20 · 2021: 5
FWCI
10.45
Type
journal article
Language
en
Open access
Locations
  • Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Association pour la recherche sur le cancer
  • BioTechMed
  • University of Graz (Fast4Health)
  • Université Paris-Saclay, Plateforme Imagerie
  • Île de France (DIM Elicit)
  • Ligue Contre le Cancer
  • Natural Science Foundation of Hubei Province (2020CFA026)
  • Agence National de la Recherche (Projets blancs)
  • European Union
  • Fondation pour la Recherche Médicale
  • High-end Foreign Expert Program in China (GDW20171100085)
  • Fondation Carrefour
  • IdEx Université de Paris ANR (18-IDEX-0001)
  • Labex (ANR-18-IDEX-0001)
  • Austrian Federal Ministry of Education, Science and Research (BMWFW-80.109/0001-WF/V/3b/2015))
  • Austrian Science Fund (W1226, P27893, P29203,P29262,P31727, SFB LIPOTOX F3007 & F3012)
  • Chinese Scholarship Council
  • AMMICa (US23/CNRS UMS3655)
  • Association Ruban Rose
  • Canceropôle Île de France
  • Elior
  • Equipex Onco-Pheno-Screen
  • European Joint Program on Rare Disease
  • Gustave Roussy (Odyssea)
  • European Union Horizon 2020 Projects (Oncobiome and Crimson)
  • Institut National Du Cancer
  • INSERM
  • Institut Universitaire de France
  • RHU Torino Lumière
  • Seerave Foundation
  • SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination
  • SIRIC Cancer Research and Personalized Medicine
  • NAWI Granz (BioHealth)
  • BioTechMed-Graz (EPIAge)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
Keywords
IGF-1 receptor, picropodophyllin, autophagy, AKT1, chemoimmunotherapy, anti-PD-1 therapy, regulatory T cells, triple-negative breast cancer, combination cancer therapy, autophagy enhancers
MeSH terms
Animals, Antineoplastic Agents, Autophagy, Female, Humans, Receptor, IGF Type 1, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: IGF1 receptor inhibition amplifies the effects of cancer drugs by autophagy and immune-dependent mechanisms. https://app.cochat.ai/papers/10.1136/jitc-2021-002722
The paper
Wu, Q., Tian, A.-L., Li, B., Leduc, M., Forveille, S., Hamley, P., Galloway, W., Xie, W., Liu, P., Zhao, L., Zhang, S., Hui, P., Madeo, F., Tu, Y., Kepp, O., & Kroemer, G. (2021). IGF1 receptor inhibition amplifies the effects of cancer drugs by autophagy and immune-dependent mechanisms. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2021-002722

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.